A phase II, multicentre, randomized, double-blind study with subcutaneous immunotherapy at different doses, in parallel groups and placebo controlled in patients with rhinoconjunctivitis ± asthma sensitized to Phleum pratense [Ensaio clínico de fase II, multicêntrico, aleatorizado, em dupla ocultação, com imunoterapia subcutânea em diferentes doses, em grupos paralelos, em doentes com rinoconjuntivite ± asma sensibilizados contra Phleum pratense]

Trial Profile

A phase II, multicentre, randomized, double-blind study with subcutaneous immunotherapy at different doses, in parallel groups and placebo controlled in patients with rhinoconjunctivitis ± asthma sensitized to Phleum pratense [Ensaio clínico de fase II, multicêntrico, aleatorizado, em dupla ocultação, com imunoterapia subcutânea em diferentes doses, em grupos paralelos, em doentes com rinoconjuntivite ± asma sensibilizados contra Phleum pratense]

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Asthma; Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jul 2014 According to the European Clinical Trials Database record, status changed from active, no longer recruiting to completed.
    • 14 Feb 2013 Planned end date changed from 1 May 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 14 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top